- Home
- FDMT vs MCI Comparison
FDMT vs MCI Comparison
Compare FDMT & MCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDMT
- MCI
- Stock Information
- Founded
- FDMT 2013
- MCI 1971
- Country
- FDMT United States
- MCI United States
- Employees
- FDMT N/A
- MCI N/A
- Industry
- FDMT Biotechnology: Pharmaceutical Preparations
- MCI Trusts Except Educational Religious and Charitable
- Sector
- FDMT Health Care
- MCI Finance
- Exchange
- FDMT Nasdaq
- MCI Nasdaq
- Market Cap
- FDMT 391.8M
- MCI 411.5M
- IPO Year
- FDMT 2020
- MCI N/A
- Fundamental
- Price
- FDMT $10.58
- MCI $21.20
- Analyst Decision
- FDMT Strong Buy
- MCI
- Analyst Count
- FDMT 9
- MCI 0
- Target Price
- FDMT $30.33
- MCI N/A
- AVG Volume (30 Days)
- FDMT 894.9K
- MCI 40.4K
- Earning Date
- FDMT 11-10-2025
- MCI 01-01-0001
- Dividend Yield
- FDMT N/A
- MCI 8.46%
- EPS Growth
- FDMT N/A
- MCI N/A
- EPS
- FDMT N/A
- MCI 1.82
- Revenue
- FDMT $120,000.00
- MCI N/A
- Revenue This Year
- FDMT $8,572.97
- MCI N/A
- Revenue Next Year
- FDMT $6.05
- MCI N/A
- P/E Ratio
- FDMT N/A
- MCI $9.88
- Revenue Growth
- FDMT 605.88
- MCI N/A
- 52 Week Low
- FDMT $2.24
- MCI $12.96
- 52 Week High
- FDMT $12.34
- MCI $19.24
- Technical
- Relative Strength Index (RSI)
- FDMT 51.91
- MCI 58.62
- Support Level
- FDMT $10.15
- MCI $20.44
- Resistance Level
- FDMT $11.18
- MCI $21.50
- Average True Range (ATR)
- FDMT 0.91
- MCI 0.55
- MACD
- FDMT -0.09
- MCI 0.05
- Stochastic Oscillator
- FDMT 44.55
- MCI 88.53
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.